Regulatory function of a malleable protein matrix as a novel fermented whey product on features defining the metabolic syndrome

Journal of Medicinal Food

Volumn 13, Issue 3, 2010, Pages 509-519

  Beaulieu, J ^a   Millette, E ^a   Trottier, E ^a   Precourt L P ^a   Dupont, C ^a   Lemieux, P ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cholesterol; dyslipidemia; fermented whey; hyperglycemia; hypertension; metabolic syndrome; probiotic; triglyceride

Indexed keywords

CHOLESTEROL; ENALAPRIL MALEATE; GLUCOSE; IMMUNOMODULATING AGENT; MALLEABLE PROTEIN MATRIX; METFORMIN; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; HYPERTENSION; LACTOBACILLUS KEFIRANOFACIENS; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; SYRIAN HAMSTER; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WHEY;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; FERMENTATION; HUMANS; HYPOGLYCEMIC AGENTS; LACTOBACILLUS; MALE; MESOCRICETUS; METABOLIC SYNDROME X; MILK PROTEINS; RANDOM ALLOCATION; RATS; RATS, INBRED SHR;

ANIMALIA; LACTOBACILLUS KEFIRANOFACIENS; MESOCRICETUS AURATUS; RATTUS;

EID: 77953735375     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2009.0083     Document Type: Article

References (53)

1. Appel SJ, Jones ED, Kennedy-Malone L: Central obesity and the metabolic syndrome: implications for primary care providers. J Am Acad Nurse Pract 2004;16:335-342.
2. Mardarowicz G, Lopatynski J, Nicer T: Metabolic syndrome. Ann Univ Mariae Curie Sklodowska [Med] 2003;58:426-431.
3. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR: Metabolic syndrome: definition, pathophysiology, and mechanisms. AmHeart J 2005;149:33-45.
4. Morales PA, Mitchell BD, Valdez RA, et al.: Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes 1993;42:154-161.
5. Haffner SM: Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl 1997;15:S25-S30.
6. Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.
7. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6: 772-783.
8. Pilote D: Optimisation des conditions de fermentation de la souche ES R2C2 pour la valorisation du lactosérum [M.S. Thesis]. INRSInstitut Armand-Frappier, Laval, QC, Canada, 2002, p. 162.
9. Simard E, Pilote D, Dupont C, et al.: Malleable protein matrix and uses thereof. Patent WO=2003=053158. December 20, 2002.
10. Beaulieu J, Dubuc R, Beaudet N, Dupont C, Lemieux P: Immunomodulation by a malleable matrix composed of fermented whey proteins and lactic acid bacteria. J Med Food 2007;10:67-72.
11. Beaulieu J, Dupont C, Lemieux P: Anti-inflammatory potential of a malleable matrix composed of fermented whey proteins and lactic acid bacteria in an atopic dermatitis model. J Inflamm (Lond) 2007;4:6.
12. Beaulieu J, Girard D, Dupont C, Lemieux P: Inhibition of neutrophil infiltration by a malleable protein matrix of lactic acid bacteria-fermented whey proteins in vivo. Inflamm Res 2009;58: 133-138.
13. Walzem RL, Dillard CJ, German JB: Whey components: millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking. Crit Rev Food Sci Nutr 2002;42:353-375.
14. Sipola M, Finckenberg P, Santisteban J, et al.: Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol 2001;52:745-754.
15. FitzGerald RJ, Murray BA, Walsh DJ: Hypotensive peptides from milk proteins. J Nutr 2004;134:980S-988S.
16. Agerholm-Larsen L, Bell ML, Grunwald GK, Astrup A: The effect of a probiotic milk product on plasma cholesterol: a metaanalysis of short-term intervention studies. Eur J Clin Nutr 2000; 54:856-860.
17. Kikuchi-Hayakawa H, Onodera-Masuoka N, Kano M, et al.: Effect of soy milk and bifidobacterium-fermented soy milk on plasma and liver lipids in ovariectomized Syrian hamsters. J Nutr Sci Vitaminol (Tokyo) 2000;46:105-108.
18. Kawase M, Hashimoto H, Hosoda M, Morita H, Hosono A: Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J Dairy Sci 2000;83:255-263.
19. Nash VJ, Johnston TP, Palmer WK: Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy 1996; 16:10-15.
20. Wasan KM, Subramanian R, Kwong M, et al.: Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J Pharm Pharm Sci 2003;6:189-197.
21. Marz W, Siekmeier R, Muller HM, et al.: Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther 2000;5:275-279.
22. Faure P, Rossini E, Wiernsperger N, et al.: An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999;48:353-357.
23. Rastelli VM, Oliveira MA, dos Santos R, et al.: Enalapril treatment corrects the reduced response to bradykinin in diabetes increasing the B2 protein expression. Peptides 2008;29:404-411.
24. Johnston TP, Palmer WK: Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993;46: 1037-1042.
25. Lemieux C, Gelinas Y, Lalonde J, et al.: Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors. J Lipid Res 2005;46:1285-1294.
26. Cheung BW, Cartier LL, Russlie HQ, Sawchuk RJ: The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fundam Clin Pharmacol 2005;19:347-354.
27. Riezzo G, Chiloiro M, Russo F: Functional foods: salient features and clinical applications. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:331-337.
28. Altschul R, Hoffer A, Stephen JD: Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955;54:558-559.
29. Ganji SH, Kamanna VS, Kashyap ML: Niacin and cholesterol: role in cardiovascular disease. J Nutr Biochem 2003;14: 298-305.
30. Johnston TP: The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J Cardiovasc Pharmacol 2004;43:595-606.
31. Fernandez ML, Wilson TA, Conde K, Vergara-Jimenez M, Nicolosi RJ: Hamsters and guinea pigs differ in their plasma lipoprotein cholesterol distribution when fed diets varying in animal protein, soluble fiber, or cholesterol content. J Nutr 1999;129: 1323-1332.
32. Shefer S, Nguyen LB, Salen G, et al.: Differing effects of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities and mRNA levels in the rat. J Lipid Res 1992;33:1193-1200.
33. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
34. Rocca AS, LaGreca J, Kalitsky J, Brubaker PL: Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology 2001;142: 1148-1155.
35. Frid AH, Nilsson M, Holst JJ, Bjorck IM: Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 2005;82:69-75.
36. Gunnarsson PT, Winzell MS, Deacon CF, et al.: Glucoseinduced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 2006; 147:3173-3180.
37. Umezawa H, Aoyagi T, Ogawa K, et al.: Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot (Tokyo) 1984;37:422-425.
38. Porteri E, Rodella L, Rizzoni D, et al.: Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Blood Press 2005;14:184-192.
39. Gobbetti M, Ferranti P, Smacchi E, Goffredi F, Addeo F: Production of angiotensin-I-converting-enzyme-inhibitory peptides in fermented milks started by Lactobacillus delbrueckii subsp. bulgaricus SS1 and Lactococcus lactis subsp. cremoris FT4. Appl Environ Microbiol 2000;66:3898-3904.
40. Takano T: Anti-hypertensive activity of fermented dairy products containing biogenic peptides. Antonie Van Leeuwenhoek 2002;82: 333-340.
41. Nakamura Y, Yamamoto N, Sakai K, Takano T: Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci 1995;78:1253-1257.
42. Nakamura Y, Yamamoto N, Sakai K, et al.: Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 1995;78:777-783.
43. Abubakar A, Saito T, Kitazawa H, Kawai Y, Itoh T: Structural analysis of new antihypertensive peptides derived from cheese whey protein by proteinase K digestion. J Dairy Sci 1998;81: 3131-3138.
44. Yamamoto N, Maeno M, Takano T: Purification and characterization of an antihypertensive peptide from a yogurt-like product fermented by Lactobacillus helveticus CPN4. J Dairy Sci 1999;82: 1388-1393.
45. Nurminen ML, Sipola M, Kaarto H, et al.: Alpha-lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci 2000;66:1535-1543.
46. Zemel MB, Miller SL: Dietary calcium and dairy modulation of adiposity and obesity risk. Nutr Rev 2004;62:125-131.
47. Maeda H, Zhu X, Omura K, Suzuki S, Kitamura S: Effects of an exopolysaccharide (kefiran) on lipids, blood pressure, blood glucose, and constipation. Biofactors 2004;22:197-200.
48. Bieganowski P, Brenner C: Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 2004;117: 495-502.
49. Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H: Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002;76:1249-1255.
50. Pereira DI, Gibson GR: Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol 2002;37:259-281.
51. Brown AC, Valiere A: Probiotics and medical nutrition therapy. Nutr Clin Care 2004;7:56-68.
52. Sorrentino MJ: Implications of the metabolic syndrome: the new epidemic. Am J Cardiol 2005;96:3E-7E.
53. Meyers CD, Kashyap ML: Management of the metabolic syndrome-nicotinic acid. Endocrinol Metab Clin North Am 2004; 33:557-575.